Our publications and results
We work to the highest standards of scientific rigour and integrity.
COMP360 psilocybin in healthy participants
As part of our psilocybin treatment development programme, we partnered with the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London to run a study with healthy volunteers.
COMP360 psilocybin treatment in TRD
The New England Journal of Medicine publishes results from phase 2b trial of investigational COMP360 psilocybin treatment for treatment-resistant depression
COMP360 psilocybin treatment in TRD with antidepressants
Compass Pathways announces positive outcome in exploratory study of investigational COMP360 psilocybin treatment with SSRI antidepressants in treatment-resistant depression
Therapist training: Frontiers in Psychiatry
A paper written by Compass Pathways with a group of academic researchers on its therapist training programme was published in Frontiers in Psychiatry in February 2021.